Filing Flows › TG Therapeutics (TGTX) › Who owns the stock
Who owns TG Therapeutics (TGTX) stock
410 funds reported TG Therapeutics (TGTX) shares in their latest 13F filings, worth $6.4B in all. The largest holder is BlackRock ($1.2B). Last quarter 219 funds added to their stakes and 147 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 22,050,045 | $1.2B | decrease | 2026-06-30 |
| Vanguard Group | 15,841,002 | $472M | increase | 2025-12-31 |
| Vanguard Portfolio Management LLC | 7,963,266 | $438M | decrease | 2026-06-30 |
| State Street | 7,786,471 | $428M | decrease | 2026-06-30 |
| Vanguard Capital Management LLC | 6,149,403 | $338M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 3,642,216 | $200M | increase | 2026-06-30 |
| D. E. Shaw | 3,400,808 | $187M | increase | 2026-06-30 |
| Soleus Capital Management, L.P. | 2,927,895 | $161M | decrease | 2026-06-30 |
| Price T Rowe Associates | 2,767,656 | $152M | increase | 2026-06-30 |
| Clearbridge Investments, LLC | 2,650,192 | $146M | decrease | 2026-06-30 |
| Two Sigma Investments, LP | 2,468,971 | $136M | increase | 2026-06-30 |
| Barclays | 2,423,794 | $135M | increase | 2026-09-30 |
| Goldman Sachs Group | 2,314,279 | $127M | increase | 2026-06-30 |
| Pictet Asset Management Holding SA | 1,785,951 | $98.1M | increase | 2026-06-30 |
| Jane Street Group, LLC | 1,752,646 | $96.3M | decrease | 2026-06-30 |
TG Therapeutics' latest quarter
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most TGTX stock?
By the latest 13F filings: BlackRock ($1.2B); Vanguard Group ($472M); Vanguard Portfolio Management LLC ($438M); State Street ($428M); Vanguard Capital Management LLC ($338M).
What is the short interest in TGTX?
29,586,873 shares were sold short at the 2026-10-15 settlement, -3.42% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.